Redwire's space pharmaceutical subsidiary, SpaceMD, has secured the inaugural operational mission of SpaceX's Starfall vehicle, marking a significant step toward the commercial production of drugs in low Earth orbit. The move positions SpaceMD to potentially create the first physical product manufactured beyond Earth, a milestone that could transform treatments for diseases ranging from cancer to Alzheimer's.
Until now, the only successful commercial space products have been Earth observation and satellite communications. Drug manufacturing in microgravity has been explored for decades on the Space Shuttle and the International Space Station, but SpaceMD's use of Starfall represents a leap forward toward routine pharmaceutical production in orbit.
The Starfall spacecraft, which first flew on a Falcon 9 on June 23 as a test, is a disk-shaped vehicle about 2.5 feet tall and 10.2 feet in diameter, weighing roughly 4,600 pounds. It can carry about 2,200 pounds of cargo, housed in an aluminum top plate that weighs about 3,090 pounds, with a detachable carbon-fiber heat shield for reentry. A typical mission would deliver a payload to low Earth orbit, remain there for a period, then reenter and splash down in the ocean.
SpaceMD's mission, currently scheduled for 2028, will carry up to 32 Pharmaceutical In-Space Laboratory units, or PIL-BOXes, to crystallize drug compounds in microgravity. This approach aims to develop improved formulations and new therapeutics. Redwire has already flown versions of the PIL-BOX on the ISS, but Starfall will greatly expand its capacity for orbital drug research.
According to Tech Times, SpaceMD will be able to process over 100 distinct drug compounds in a single Starfall mission, compared to the 45 compounds crystallized on the ISS to date, including insulin and candidates for cancer, cardiovascular disease, obesity, and diabetes. The microgravity environment eliminates gravity and temperature differentials that degrade crystal quality on Earth, resulting in larger, more orderly crystals. As Tech Times notes, drug crystal structure directly affects dissolution rate, solubility, and bioavailability—how quickly and completely an active ingredient enters the bloodstream.
Growing the crystals is only the first step. SpaceMD has a licensing agreement with ExesaLibero Pharma to develop drugs from those crystals and navigate the arduous process of clinical trials and regulatory approval. In return, Redwire's subsidiary will receive royalties on any drugs ExesaLibero brings to market using space-grown crystals.
The potential impact is profound. The National Cancer Institute estimates over 2.1 million new cancer diagnoses in 2026, with 626,140 deaths. The Centers for Disease Control and Prevention reports that 6.7 million American adults live with Alzheimer's, a figure projected to double by 2060. Any treatment that reduces those numbers could alleviate immense human suffering and healthcare costs.
Critics have long dismissed space exploration as a luxury or a distraction from earthly problems. Senator Bernie Sanders (I-Vt.) has attacked commercial space figures like Elon Musk and Jeff Bezos, despite their work for NASA and the Defense Department. But the argument that space development is inherently wasteful is becoming untenable as tangible benefits emerge. The successful ocean landing of SpaceX's Starship and the upcoming ISS spacewalks underscore the growing capabilities in orbit.
As Redwire and others push forward, the flow of real-world benefits from space is set to become a flood. Better, more effective drugs will be just one of the dividends of the new commercial space age.
